Jobs / United States / Glaxosmithkline LLC
Director, Quantitative Systems Pharmacology
Glaxosmithkline LLC · 🇺🇸 5 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Glaxosmithkline LLC paid sponsored hires in similar roles4 certified filings for “Associate Director – Genomic Technologies” (Molecular and Cellular Biologists) in PA: $134k–$138k, median $136k. Most were filed at wage level IV (50%) — 4 lottery entries, ≈61% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Glaxosmithkline LLC
The US Department of Labor certified 39 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 15 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Glaxosmithkline LLC →
About the role
Business Introduction At GSK, we have bold ambitions for patients, aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines, combining our understanding of the immune system with cutting-edge technology to transform people’s lives. GSK fosters a culture ambitious for patients, accountable for impact, and committed to doing the right thing, making sure that we focus our efforts on accelerating significant assets that meet patients’ needs and have the highest probability of success. We’re uniting science, technology, and talent to get ahead of disease together. Find out more: Our approach to R&D Director, Quantitative Systems Pharmacology For candidates seeking to be located at our Stevenage site, this role will temporarily be based at Stevenage. However, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029. The Department of Clinical Pharmacology and Quantitative Medicine (CPQM) in the GSK Respiratory, Immunology and Inflammation Research Unit is recruiting for a Quantitative Systems Pharmacologist Lead. At GSK, CPQM is a newly established organization with the remit to become a Centre of Excellence in Model-Informed Drug Development (MIDD). It uniquely integrates clinical pharmacology, digital medicine, translational imaging, and mechanistic & systems modeling. The convergence of science and technology is changing discovery and development at GSK, allowing us to make advances on behalf of patients that were once thought impossible. Our R&D organization is delivering more innovation, better and faster, using new data and platform technologies that speed up discovery and development and improve the chance of success. This position represents a key opportunity for professionals with PhD, MD, or PharmD, who are experienced mechanistic modelers with experience in QSP and/or QST modeling, clinical pharmacology and pharmacometrics, to join the Quantitative Systems Pharmacology team to advance the vision and mission of GSK’s rapidly expanding Respiratory, Inflammation and Immunology Disease portfolio. Sought after experiences for this position include building mechanistic mathematical models and leveraging knowledge in the areas of scientific ML, inverse problems, AIML and/or statistical methodologies, to enhance the robustness and quality of model development to leverage for decision-making from exploratory research through clinical development. You will be expected to play a critical role in the day-to-day driving integration of end-to-end model-informed drug discovery and development through building and applying mechanistic QSP and QST models. In addition, you will be defining, implementing and coordinating QSP and QST related Clinical Pharmacology and Quantitative Medicine development strategies for disease and therapeutics of interest, and providing expert input into the clinical pharmacology evidence generation and integrated evidence plans in the Disease therapeutic area. This is an exciting opportunity to bring your vision and leadership to a new era of digital innovation in clinical pharmacology and quantitative medicine, profoundly impacting patient outcomes and shaping the future of R&D at GSK. Main responsibilities and accountabilities also include: · Build and/or guide mathematical model development to understand disease, its progression, and drug action to prevent, treat and cure diseases; conduct simulations to assess trial design performance · Apply mechanistic models of biological, physiolo